<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346788</url>
  </required_header>
  <id_info>
    <org_study_id>CDHA-RL-001</org_study_id>
    <nct_id>NCT00346788</nct_id>
  </id_info>
  <brief_title>The Subvastus Approach in Total Knee Arthroplasty</brief_title>
  <official_title>The Subvastus Approach in Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the observed benefits of minimally invasive
      total knee arthroplasty, namely decreased hospital stay and increased range of motion, can be
      achieved with standard knee arthroplasty using the subvastus approach.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Post Operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Range of motion at discharge and six weeks post-operatively</measure>
    <time_frame>Discharge and six weeks post operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound complications</measure>
    <time_frame>post operative until wound healed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative narcotic use</measure>
    <time_frame>24 months post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative blood loss</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ability to straight-leg raise at two and twenty-four hours post-operatively</measure>
    <time_frame>2 and 24 hours post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Society Clinical Rating Scale</measure>
    <time_frame>pre-op, 6 months, 12 months, and 24 months post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12</measure>
    <time_frame>pre-op, 6 months, 12 months, and 24 months post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC.</measure>
    <time_frame>pre-op, 6 months, 12 months, and 24 months post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>MIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>minimally invasive incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard incision length</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical approach for total knee arthroplasty</intervention_name>
    <description>total knee arthroplasty surgery using minimally invasive surgery or standard technique.</description>
    <arm_group_label>MIS</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You are willing to take part in the study, including signing this form after carefully
             reading it.

          -  You are available for follow-up for a minimum of 24 months (2 years).

          -  You have no medical conditions that prevent you from having surgery.

          -  This is the primary (first) knee replacement for this knee

          -  You are fluent in English and are able to understand your responsibilities in this
             study.

        Exclusion Criteria:

          -  Active, local or systemic infection

          -  Fibromyalgia or other chronic pain syndrome

          -  Inability to follow the study requirements

          -  Had this knee replaced before

          -  Had a previous surgery on this knee that would interfere with the MIS approach
             (examples are femoral-femoral bypass, femoral-popliteal bypass, and quadricepsplasty)

          -  Body Mass Index (BMI) &gt; 35, as you would not be eligible for the MIS approach.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross K Leighton, MD, FRCS(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Health, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>June 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2006</study_first_posted>
  <last_update_submitted>June 27, 2011</last_update_submitted>
  <last_update_submitted_qc>June 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ross K. Leighton</name_title>
    <organization>Capital District Health Authority, Canada</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

